CME Unit Earns Accreditation with Commendation

UC’s Continuing Medical Education (CME) department has received its reaccreditation decision from the Accreditation Council for Continuing Medical Education (ACCME) as "Accreditation with Commendation” —the highest recognition awarded by ACCME.

Accreditation with Commendation is awarded to providers that demonstrate compliance in all 22 criteria and the accreditation policies. The accreditation will last for six years. 

Only 21 percent of national CME providers have achieved Accreditation with Commendation.

The ACCME’s process for evaluating CME programs holds to the high accreditation standards adopted by seven ACCME member organizations. Accreditation with Commendation is awarded to providers that demonstrate compliance in all 22 criteria and the accreditation policies.

In a letter announcing the accreditation, ACCME Chief Executive Murray Kopelow, MD, said the designation demonstrates that UC’s CME department is "a learning organization and a change agent” for the physicians it serves. 

The reaccreditation team was led by department director Susan Tyler under the guidance of Jack Kues, PhD, associate dean for continuous professional development.

"I want to applaud the fantastic effort of the entire CME and CPD staff that went into our 18-month self-study process,” says Tyler. "We are delighted to have our hard work recognized by our national accreditor and our peer organizations.”

Other staff members in the Center for Continuous Professional Development include associate director Barb Speer, Kathy Levi, Barbara Forney, Deborah Cole, Mary Ellen Gallo, Josh Rountree and Justin Slamka. Retired CME program directors Lynn Fischer and Kay Weigand are also to be recognized for their contributions during this accreditation period.

Tags

Related Stories

2

At least two weather patterns increase headaches, UC study suggests

June 4, 2026

University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.